Drew Barrymore, Women's HRT, and How a Regular Patient Gets Access

What Drew Barrymore Has Said About Perimenopause

Drew Barrymore has been direct about her perimenopause experience. On her daytime talk show "The Drew Barrymore Show" and in subsequent press interviews, she described symptoms including mood changes, disrupted sleep, and what she called a sense of feeling unlike herself. She framed the conversation as one women should not have to keep quiet, and she invited OB-GYNs onto her show to discuss treatment options in plain language.

This is worth noting for clinical context: Barrymore has not confirmed a specific HRT regimen publicly as of this writing. Any claim that she takes a particular drug or dose would be inference, and this article labels it as such. What she has done is normalize the conversation around perimenopause treatment, which research suggests benefits patients. A 2021 survey published by The Menopause Society found that women who heard peers or public figures discuss menopause openly were significantly more likely to seek a provider consultation within six months.

Why Celebrity Disclosure Matters Clinically

Public figures talking about perimenopause reduce the average delay between symptom onset and treatment. The average woman waits 4.5 years after first experiencing vasomotor symptoms before receiving any hormonal treatment, according to data from the SWAN (Study of Women's Health Across the Nation) longitudinal cohort. That gap carries real costs: sustained vasomotor symptoms are associated with a 40% higher risk of sleep disorder diagnoses and measurable reductions in work productivity.

Barrymore occupies a cultural space that reaches women in their late 30s through early 50s, precisely the perimenopause window. Her candor is a prompt, not a prescription. The prescription part requires a licensed clinician.

What Is Women's HRT and Who Qualifies?

Women's hormone replacement therapy replaces estrogen (and, when a uterus is present, progestogen) that the ovaries produce less of during perimenopause and menopause. The primary evidence-based indication is moderate-to-severe vasomotor symptoms. Secondary indications include genitourinary syndrome of menopause (GSM), prevention of bone loss in women at elevated fracture risk, and management of premature ovarian insufficiency (POI) in women under 40.

The Core Hormone Regimens

Estrogen-only therapy (ET) is appropriate for women who have had a hysterectomy. The most prescribed formulation in the United States is 17-beta estradiol, available as an oral tablet (0.5 to 2 mg daily), a transdermal patch (0.025 to 0.1 mg/day), a topical gel, or a vaginal ring for systemic delivery.

Combined estrogen-progestogen therapy (EPT) is required for women with an intact uterus. Adding a progestogen protects the endometrium from estrogen-driven hyperplasia. Micronized progesterone 200 mg for 12 days per cycle (sequential) or 100 mg nightly (continuous combined) is the most widely used approach in current U.S. Practice, consistent with The Menopause Society 2022 Position Statement. [1]

Bioidentical hormones is a marketing term, not a pharmacological category. FDA-approved estradiol and micronized progesterone are chemically identical to endogenous hormones. Compounded "BHRT" products lack the same efficacy and safety data and are not recommended as a first choice by The Menopause Society or the Endocrine Society. [2]

Who Is a Good Candidate?

The Menopause Society states: "For women aged younger than 60 years or within 10 years of menopause onset who do not have contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms." [1]

Absolute contraindications include unexplained vaginal bleeding, active or history of breast cancer (estrogen-receptor positive), active cardiovascular disease (recent MI or stroke), active venous thromboembolism, and known thrombophilia.

Relative contraindications (requiring individual risk-benefit discussion) include controlled hypertension, migraine with aura, and personal history of VTE more than five years prior.

The Evidence Behind HRT: Key Trials You Should Know

The clinical case for HRT has strengthened considerably since the Women's Health Initiative (WHI) alarmed clinicians in 2002. Reading the WHI headline without reading its subsequent re-analyses misrepresents current science.

Women's Health Initiative: The Corrected Picture

The original 2002 WHI publication reported increased breast cancer and cardiovascular risk with conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA). Subsequent analyses showed the risk increase was concentrated in women who were more than 10 years past menopause at enrollment, many of whom already had subclinical cardiovascular disease. [3]

The WHI estrogen-only arm (women post-hysterectomy receiving CEE alone) showed a statistically significant 23% reduction in breast cancer incidence at 18 years of follow-up (HR 0.78, 95% CI 0.65 to 0.93, P<0.001). [4] That finding directly contradicts the popular assumption that "estrogen causes breast cancer."

The Timing Hypothesis: Evidence from the Danish Osteoporosis Prevention Study

The Danish Osteoporosis Prevention Study (DOPS) randomized 1,006 recently postmenopausal women to HRT or no treatment and followed them for 10 years. Women on HRT had a significantly lower rate of the composite endpoint of heart failure, MI, and cardiovascular mortality (HR 0.48, 95% CI 0.26 to 0.87, P=0.015) compared to controls. [5] Timing, meaning starting HRT close to menopause onset rather than years later, is the variable that drives cardiovascular benefit.

Breast Cancer Risk in Perspective

The most cited modern analysis, a 2019 Lancet meta-analysis by the Collaborative Group on Hormonal Factors in Breast Cancer (N=108,647 women with breast cancer), found that 5 years of EPT use was associated with approximately 1 additional case of breast cancer per 50 users. [6] That absolute risk increase is smaller than the risk associated with consuming two alcoholic drinks per day or having a BMI above 30. Context matters.

How a Regular Patient Actually Gets Access to HRT

Getting HRT does not require a celebrity platform or a specialist waiting list measured in months. Here is the practical path.

Step 1: Identify Your Symptoms and Track Them

Hot flashes, night sweats, irregular periods, mood changes, brain fog, vaginal dryness, and disrupted sleep are the most common perimenopause symptoms. Before your first appointment, log frequency and severity for at least two weeks. The validated Menopause Rating Scale (MRS) is a free 11-item questionnaire available from the Berlin Center for Epidemiology and Health Research and takes under five minutes to complete.

Tracking gives your provider objective data and speeds the consultation.

Step 2: Choose Your Provider Type

You have three practical options:

Primary care physician or internist. Most can prescribe standard HRT. Referral to an OB-GYN or menopause specialist is warranted for complex cases (early menopause, significant comorbidities, prior hormone-sensitive cancer).

OB-GYN or Menopause Society-certified menopause practitioner. The Menopause Society maintains a searchable directory of certified practitioners at menopause.org. As of 2024, there are roughly 1,200 certified menopause practitioners in the United States, a number that has grown 30% since 2020.

Telehealth menopause platform. Synchronous video visits are now available in all 50 states for HRT prescribing. Turnaround from intake form to pharmacy-sent prescription is typically 24 to 72 hours. HealthRX clinicians can evaluate perimenopause symptoms, review labs, and prescribe FDA-approved estradiol and micronized progesterone without an in-person visit for eligible patients.

Step 3: Baseline Lab Work

Labs are not always mandatory before starting HRT for a woman with clear clinical symptoms, but they rule out confounders and establish a safety baseline. Standard panel:

• FSH (follicle-stimulating hormone): elevated FSH (>25 IU/L on two samples 4 to 6 weeks apart) supports a menopause diagnosis, though perimenopause FSH fluctuates widely
• Estradiol: low levels corroborate the clinical picture
• TSH: thyroid dysfunction mimics many perimenopause symptoms
• Lipid panel: baseline cardiovascular risk assessment
• Blood pressure: hypertension is a relative contraindication to oral estrogen; transdermal routes bypass first-pass hepatic metabolism and carry lower VTE risk

Many telehealth platforms coordinate at-home phlebotomy or direct you to a local LabCorp or Quest draw site. Results typically return in 24 to 48 hours.

Step 4: The Prescribing Visit

A competent menopause prescribing visit covers:

1. Symptom severity and duration
2. Last menstrual period and cycle pattern
3. Personal and family history of breast cancer, VTE, cardiovascular disease, and osteoporosis
4. Current medications (tamoxifen and aromatase inhibitors are contraindications; SSRIs may affect libido baseline)
5. Patient preference for route of administration

Expect the visit to last 20 to 40 minutes. At the end, your clinician should offer a formulation recommendation, explain the rationale, and set a follow-up date for 8 to 12 weeks.

Step 5: Starting Therapy and Titrating

Most providers start with the lowest effective dose. A typical starting regimen for a woman with an intact uterus:

• Estradiol transdermal patch 0.05 mg/day (changed twice weekly)
• Micronized progesterone 100 mg orally at bedtime nightly (continuous combined)

After 8 to 12 weeks, hot flash frequency and severity should drop by at least 75% from baseline if the dose is adequate. If response is partial, estradiol can be uptitrated to 0.075 mg or 0.1 mg/day. Full hot flash elimination is not the universal goal; meaningful symptom reduction with good tolerability is.

Step 6: Ongoing Monitoring

Annual visits should include blood pressure check, breast exam discussion, and mammography coordination per the American Cancer Society schedule. No routine endometrial biopsy is needed in asymptomatic women on correctly dosed continuous combined EPT. Any unscheduled vaginal bleeding warrants prompt evaluation.

The HealthRX Perimenopause Access Framework summarizes the above as a six-step clinical pathway: symptom logging, provider selection, baseline labs, prescribing visit, therapy initiation, and annual monitoring. This framework maps directly onto The Menopause Society's recommended management sequence and is designed for use by both patients and non-specialist clinicians onboarding to menopause care.

Transdermal vs. Oral Estrogen: Why the Route Matters

Route of administration is not a trivial preference. It changes the pharmacokinetics and the risk profile in ways patients deserve to understand.

Oral Estrogen

Oral estradiol and conjugated equine estrogens undergo first-pass hepatic metabolism. This raises sex hormone-binding globulin (SHBG) and C-reactive protein, modestly elevates triglycerides, and increases the synthesis of clotting factors. The net result is a small but real increase in VTE risk. The ESTHER study (a French case-control study, N=881 cases) found that oral estrogen users had a VTE odds ratio of 3.5 (95% CI 1.8 to 6.8) compared to non-users, while transdermal users showed no significant increase (OR 0.9, 95% CI 0.5 to 1.6). [7]

Transdermal Estrogen

Patches, gels, and sprays deliver estradiol directly into systemic circulation, bypassing hepatic first-pass. Triglycerides, SHBG, and clotting factor synthesis remain essentially unchanged. For women with hypertension, migraine with aura, obesity, or personal VTE history, transdermal estradiol is the preferred formulation per ACOG Practice Bulletin 141. [8]

The tradeoff: skin irritation at patch sites affects roughly 10 to 15% of users, and gel/spray formulations require care around skin-to-skin transfer to partners or children.

Non-Hormonal Alternatives: When HRT Is Not the Right Fit

Some women are not candidates for systemic estrogen, and some prefer to avoid it. FDA-approved non-hormonal options now exist.

Fezolinetant (Veozah, Astellas) received FDA approval in May 2023 as the first non-hormonal prescription drug specifically for moderate-to-severe vasomotor symptoms. It is a neurokinin 3 (NK3) receptor antagonist that acts on the hypothalamic thermoregulatory pathway. In the SKYLIGHT 1 trial (N=501), fezolinetant 45 mg once daily reduced moderate-to-severe hot flash frequency by 60.4% from baseline at week 12 vs. 45.4% with placebo. [9]

Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved SSRI for vasomotor symptoms, though its effect size is modest: roughly 33 to 65% reduction in hot flash frequency depending on the trial.

Oxybutynin is used off-label. A small randomized trial (N=150) found 2.5 to 5 mg daily reduced hot flash scores by 52% compared to 26% for placebo at 12 weeks. [10]

Cognitive behavioral therapy (CBT) delivered over six weekly sessions has shown a 50% reduction in hot flash problem-rating scores in the MENOS 2 trial (N=96), making it a clinically meaningful non-pharmacological option for women who prefer it. [11]

Cost and Insurance: Practical Numbers

Generic estradiol patch 0.05 mg/day (8 patches, a 4-week supply): approximately $30, $60 at major U.S. Pharmacies without insurance.

Micronized progesterone 100 mg capsules (30 capsules): approximately $25, $50 generic.

GoodRx and similar discount programs regularly bring these under $40 combined per month. Most commercial insurance plans cover FDA-approved HRT formulations, though prior authorization requirements vary by carrier.

Fezolinetant (Veozah) listed at roughly $550/month at launch; patient assistance programs are available through Astellas for qualifying patients.

Telehealth visit cost: typically $75, $150 for the initial evaluation at most platforms, with follow-ups at $50, $99.

The Menopause Society and Endocrine Society Guidelines: What They Actually Say

Both major guideline bodies agree on core principles. Specific language from The Menopause Society 2022 Position Statement: "Hormone therapy remains the most effective treatment for vasomotor symptoms and is also effective for the genitourinary syndrome of menopause and for prevention of bone loss and fracture." [1]

The Endocrine Society 2015 Clinical Practice Guideline on Menopause adds: "We suggest against the routine use of compounded bioidentical hormone therapy... Due to lack of evidence for safety and efficacy compared to FDA-approved products." [2]

ACOG Practice Bulletin 141 (reaffirmed 2023) states that for symptomatic women without contraindications, systemic hormone therapy is appropriate and should not be arbitrarily limited in duration based on age alone. [8] That last clause matters. Many women have been told to stop HRT at five years regardless of symptoms. Current evidence does not support a universal five-year cap.